COVID-19 mRNA vaccines demonstrate over 90% efficacy and strong immunogenicity, but face challenges in durability and balancing immune stimulation with adverse effects ranging from mild reactogenicity to rare severe diseases.
This review provides mechanistic insights into the immune responses and adverse effects of COVID-19 mRNA vaccines, highlighting the challenge of balancing immunogenicity and reactogenicity.
Since the discovery of messenger RNA (mRNA), there have been tremendous efforts to wield them in the development of therapeutics and vaccines. During the COVID-19 pandemic, two mRNA vaccines were developed and approved in record-breaking time, revolutionizing the vaccine development landscape. Although first-generation COVID-19 mRNA vaccines have demonstrated over 90% efficacy, alongside strong immunogenicity in humoral and cell-mediated immune responses, their durability has lagged compared to long-lived vaccines, such as the yellow fever vaccine. Although worldwide vaccination campaigns have saved lives estimated in the tens of millions, side effects, ranging from mild reactogenicity to rare severe diseases, have been reported. This review provides an overview and mechanistic insights into immune responses and adverse effects documented primarily for COVID-19 mRNA vaccines. Furthermore, we discuss the perspectives of this promising vaccine platform and the challenges in balancing immunogenicity and adverse effects.
Lee et al. (Mon,) conducted a review in COVID-19. mRNA vaccines was evaluated. COVID-19 mRNA vaccines demonstrate over 90% efficacy and strong immunogenicity, but face challenges in durability and balancing immune stimulation with adverse effects ranging from mild reactogenicity to rare severe diseases.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: